Modern approach to the management of genitourinary syndrome in women with gynecological malignancies

1. Hailu HE, Mondul AM, Rozek LS, Geleta T. Descriptive epidemiology of breast and gynecological cancers among patients attending Saint Paul's Hospital Millennium Medical College, Ethiopia. PLoS One 2020; 15: e0230625. doi: 10.1371/journal.pone.0230625 HailuHE MondulAM RozekLS GeletaT Descriptive epidemiology of breast and gynecological cancers among patients attending Saint Paul's Hospital Millennium Medical College, Ethiopia PLoS One 2020 15 e0230625 10.1371/journal.pone.0230625 Open DOISearch in Google Scholar

2. Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, et al. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: a Society of Gynecologic Oncology (SGO) clinical practice statement: this practice statement has been endorsed by the North American Menopause Society. Gynecol Oncol 2020; 157: 303–6. doi: 10.1016/j.ygyno.2020.01.035 SinnoAK PinkertonJ FebbraroT JonesN KhannaN TemkinS Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: a Society of Gynecologic Oncology (SGO) clinical practice statement: this practice statement has been endorsed by the North American Menopause Society Gynecol Oncol 2020 157 303 6 10.1016/j.ygyno.2020.01.035 Open DOISearch in Google Scholar

3. Mension E, Alonso I, Castelo-Branco C. Genitourinary syndrome of menopause: current treatment options in breast cancer survivors - systematic review. Maturitas 2021; 143: 47–58. doi: 10.1016/j.maturitas.2020.08.010 MensionE AlonsoI Castelo-BrancoC Genitourinary syndrome of menopause: current treatment options in breast cancer survivors - systematic review Maturitas 2021 143 47 58 10.1016/j.maturitas.2020.08.010 Open DOISearch in Google Scholar

4. Portman DJ, Gass MLS; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014; 21: 1063–8. doi:10.1097/GME.0000000000000329 PortmanDJ GassMLS Vulvovaginal Atrophy Terminology Consensus Conference Panel Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society Menopause 2014 21 1063 8 10.1097/GME.0000000000000329 Open DOISearch in Google Scholar

5. Farrell Am E. Genitourinary syndrome of menopause. Aust Fam Physician 2017; 46: 481–4. PMID: 28697291 Farrell AmE Genitourinary syndrome of menopause Aust Fam Physician 2017 46 481 4 28697291 Search in Google Scholar

6. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause 2020; 27: 976–92. doi: 10.1097/GME.0000000000001609 The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society Menopause 2020 27 976 92 10.1097/GME.0000000000001609 Open DOISearch in Google Scholar

7. Aerts L, Enzlin P, Verhaeghe J, Poppe W, Vergote I, Amant F. Sexual functioning in women after surgical treatment for endometrial cancer: a prospective controlled study. J Sex Med 2015; 12: 198–209. doi: 10.1111/jsm.12764 AertsL EnzlinP VerhaegheJ PoppeW VergoteI AmantF Sexual functioning in women after surgical treatment for endometrial cancer: a prospective controlled study J Sex Med 2015 12 198 209 10.1111/jsm.12764 Open DOISearch in Google Scholar

8. Aerts L, Enzlin P, Verhaeghe J, Poppe W, Vergote I, Amant F. Long-term sexual functioning in women after surgical treatment of cervical cancer stages IA to IB: a prospective controlled study. Int J Gynecol Cancer 2014; 24: 1527–34. doi: 10.1097/IGC.0000000000000236 AertsL EnzlinP VerhaegheJ PoppeW VergoteI AmantF Long-term sexual functioning in women after surgical treatment of cervical cancer stages IA to IB: a prospective controlled study Int J Gynecol Cancer 2014 24 1527 34 10.1097/IGC.0000000000000236 Open DOISearch in Google Scholar

9. Chan JL, Letourneau J, Salem W, Cil AP, Chan SW, Chen LM, et al. Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery. Gynecol Oncol 2015; 139: 141–7. doi: 10.1016/j.ygyno.2015.07.105 ChanJL LetourneauJ SalemW CilAP ChanSW ChenLM Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery Gynecol Oncol 2015 139 141 7 10.1016/j.ygyno.2015.07.105 Open DOISearch in Google Scholar

10. Tramacere F, Lancellotta V, Casà C, Fionda B, Cornacchione P, Mazzarella C, et al. Assessment of sexual dysfunction in cervical cancer patients after different treatment modality: a systematic review. Med Kaunas Lith 2022; 58: 1223. doi: 10.3390/medicina58091223 TramacereF LancellottaV CasàC FiondaB CornacchioneP MazzarellaC Assessment of sexual dysfunction in cervical cancer patients after different treatment modality: a systematic review Med Kaunas Lith 2022 58 1223 10.3390/medicina58091223 Open DOISearch in Google Scholar

11. Kirchheiner K, Smet S, Jürgenliemk-Schulz IM, Haie-Meder C, Chargari C, Lindegaard JC, et al. Impact of vaginal symptoms and hormonal replacement therapy on sexual outcomes after definitive chemoradiotherapy in patients with locally advanced cervical cancer: results from the EMBRACE-I study. Int J Radiat Oncol Biol Phys 2022; 112: 400–13. doi: 10.1016/j.ijrobp.2021.08.036 KirchheinerK SmetS Jürgenliemk-SchulzIM Haie-MederC ChargariC LindegaardJC Impact of vaginal symptoms and hormonal replacement therapy on sexual outcomes after definitive chemoradiotherapy in patients with locally advanced cervical cancer: results from the EMBRACE-I study Int J Radiat Oncol Biol Phys 2022 112 400 13 10.1016/j.ijrobp.2021.08.036 Open DOISearch in Google Scholar

12. Gandhi J, Chen A, Dagur G, Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 2016; 215: 704–11. doi: 10.1016/j.ajog.2016.07.045 GandhiJ ChenA DagurG Y SmithN CaliB Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management Am J Obstet Gynecol 2016 215 704 11 10.1016/j.ajog.2016.07.045 Open DOISearch in Google Scholar

13. Brennan A, Brennan D, Rees M, Hickey M. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. Int J Gynecol Cancer 2021; 31: 352–9. doi: 10.1136/ijgc-2020-002032 BrennanA BrennanD ReesM HickeyM Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer Int J Gynecol Cancer 2021 31 352 9 10.1136/ijgc-2020-002032 Open DOISearch in Google Scholar

14. Laios A, Otify M, Papadopoulou A, Gallos ID, Ind T. Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis. BMC Womens Health 2022; 22: 305. doi: 10.1186/s12905-022-01887-8 LaiosA OtifyM PapadopoulouA GallosID IndT Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis BMC Womens Health 2022 22 305 10.1186/s12905-022-01887-8 Open DOISearch in Google Scholar

15. Bober SL, Reese JB, Barbera L, Bradford A, PhD, Carpenter KM, Goldfarb S, et al. How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer. Curr Opin Support Palliat Care 2016; 10: 44–54. doi: 10.1097/SPC.0000000000000186 BoberSL ReeseJB BarberaL BradfordAPhD CarpenterKM GoldfarbS How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer Curr Opin Support Palliat Care 2016 10 44 54 10.1097/SPC.0000000000000186 Open DOISearch in Google Scholar

16. Erekson EA, Yip SO, Wedderburn TS, Martin DK, Li FY, Choi, JN, et al. The vulvovaginal symptoms questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause 2013; 20: 973–9. doi: 10.1097/GME.0b013e318282600b EreksonEA YipSO WedderburnTS MartinDK LiFY ChoiJN The vulvovaginal symptoms questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women Menopause 2013 20 973 9 10.1097/GME.0b013e318282600b Open DOISearch in Google Scholar

17. Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause 2018; 25: 596–608. doi: 10.1097/GME.0000000000001121 FaubionSS LarkinLC StuenkelCA BachmannGA ChismLA KaganR Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health Menopause 2018 25 596 608 10.1097/GME.0000000000001121 Open DOISearch in Google Scholar

18. Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis D, Athanasiou S. The genitourinary syndrome of menopause: an overview of the recent data. Cureus 2020; 12: e7586. doi: 10.7759/cureus.7586 AngelouK GrigoriadisT DiakosavvasM ZacharakisD AthanasiouS The genitourinary syndrome of menopause: an overview of the recent data Cureus 2020 12 e7586 10.7759/cureus.7586 Open DOISearch in Google Scholar

19. Matos SR de L, Lucas Rocha Cunha M, Podgaec S, Weltman E, Yamazaki Centrone AF, Cintra Nunes Mafra AC. Consensus for vaginal stenosis prevention in patients submitted to pelvic radiotherapy. PloS One 2019; 14: e0221054. doi: 10.1371/journal.pone.0221054 MatosSR de L Lucas Rocha CunhaM PodgaecS WeltmanE Yamazaki CentroneAF Cintra Nunes MafraAC Consensus for vaginal stenosis prevention in patients submitted to pelvic radiotherapy PloS One 2019 14 e0221054 10.1371/journal.pone.0221054 Open DOISearch in Google Scholar

20. Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric J Int Menopause Soc 2018; 21: 167–73. doi: 10.1080/13697137.2017.1421921 MoralE DelgadoJL CarmonaF CaballeroB GuillánC GonzálezPM Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study Climacteric J Int Menopause Soc 2018 21 167 73 10.1080/13697137.2017.1421921 Open DOISearch in Google Scholar

21. George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors: letrozole in uterine leiomyosarcoma. Cancer 2014; 120: 738–43. doi: 10.1002/cncr.28476 GeorgeS FengY ManolaJ NucciMR ButrynskiJE MorganJA Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors: letrozole in uterine leiomyosarcoma Cancer 2014 120 738 43 10.1002/cncr.28476 Open DOISearch in Google Scholar

22. Didar H, Farzaneh F, Najafiarab H, Kosar Namakin K, Gohari K, Sheidaei A, et al. Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis. Curr Med Res Opin 2023; 39: 901–10. doi: 10.1080/03007995.2023.2208488 DidarH FarzanehF NajafiarabH Kosar NamakinK GohariK SheidaeiA Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis Curr Med Res Opin 2023 39 901 10 10.1080/03007995.2023.2208488 Open DOISearch in Google Scholar

23. de Hullu JA, Pras E, Hollema H, van dr Zee AGJ, Bogchelman DH, Mourits MJE. Presentations of endometrial activity after curative radiotherapy for cervical cancer. Maturitas 2005; 51: 172–6. doi: 10.1016/j.maturitas.2004.07.005 de HulluJA PrasE HollemaH van dr ZeeAGJ BogchelmanDH MouritsMJE Presentations of endometrial activity after curative radiotherapy for cervical cancer Maturitas 2005 51 172 6 10.1016/j.maturitas.2004.07.005 Open DOISearch in Google Scholar

24. Mlinarič M, Arko D, Barbič M, Alenka Pretnar-Darovec A, Darovec J, Geršak K, et al. [Expert recommendations on menopausal medicine]. [Slovenian]. Ljubljana: Slovenian Menopause Association. Medical Association of Slovenia; 2021. MlinaričM ArkoD BarbičM Alenka Pretnar-DarovecA DarovecJ GeršakK [Expert recommendations on menopausal medicine]. [Slovenian] Ljubljana Slovenian Menopause Association. Medical Association of Slovenia 2021 Search in Google Scholar

25. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JAV, et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 3975–4011. doi: 10.1210/jc.2015-2236 StuenkelCA DavisSR GompelA LumsdenMA MuradMH PinkertonJAV Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab 2015 100 3975 4011 10.1210/jc.2015-2236 Open DOISearch in Google Scholar

26. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8(Suppl 1): 3–63. doi: 10.1080/13697130500148875 KuhlH Pharmacology of estrogens and progestogens: influence of different routes of administration Climacteric 2005 8 Suppl 1 3 63 10.1080/13697130500148875 Open DOISearch in Google Scholar

27. Crean-Tate KK, Faubion SS, Pederson HJ, Vencill JA, Batur P. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. Am J Obstet Gynecol 2020; 222: 103–13. doi: 10.1016/j.ajog.2019.08.043 Crean-TateKK FaubionSS PedersonHJ VencillJA BaturP Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy Am J Obstet Gynecol 2020 222 103 13 10.1016/j.ajog.2019.08.043 Open DOISearch in Google Scholar

28. La Rosa VL, Ciebiera M, Lin LT, Fan S, Butticè S, Sathyapalan T, et al. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function. Prz Menopauzalny 2019; 18: 116–122. doi: 10.5114/pm.2019.86836 La RosaVL CiebieraM LinLT FanS ButticèS SathyapalanT Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function Prz Menopauzalny 2019 18 116 122 10.5114/pm.2019.86836 Open DOISearch in Google Scholar

29. Santen RJ, Pinkerton JV, Conaway M, Ropka M, Wisniewski L, Demers L, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002; 9: 179–87. doi: 10.1097/00042192-200205000-00006 SantenRJ PinkertonJV ConawayM RopkaM WisniewskiL DemersL Treatment of urogenital atrophy with low-dose estradiol: preliminary results Menopause 2002 9 179 87 10.1097/00042192-200205000-00006 Open DOISearch in Google Scholar

30. Chambers LM, Herrmann A, Michener CM, Ferrando CA, Ricci S. Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma. Int J Gynecol Cancer 2020; 30: 515–24. doi: 10.1136/ijgc-2019-001034 ChambersLM HerrmannA MichenerCM FerrandoCA RicciS Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma Int J Gynecol Cancer 2020 30 515 24 10.1136/ijgc-2019-001034 Open DOISearch in Google Scholar

31. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Ggnecologic Oncology Group study. J Clin Oncol 2006; 24: 587–92. doi: 10.1200/JCO.2005.02.8464 BarakatRR BundyBN SpirtosNM BellJ MannelRS Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Ggnecologic Oncology Group study J Clin Oncol 2006 24 587 92 10.1200/JCO.2005.02.8464 Open DOISearch in Google Scholar

32. Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 2014; 50: 1628–37. doi: 10.1016/j.ejca.2014.03.006 ShimSH LeeSJ KimSN Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis Eur J Cancer 2014 50 1628 37 10.1016/j.ejca.2014.03.006 Open DOISearch in Google Scholar

33. Li D, Ding C, Qiu L. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol 2015; 139: 355–62. doi: 10.1016/j.ygyno.2015.07.109 LiD DingC QiuL Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis Gynecol Oncol 2015 139 355 62 10.1016/j.ygyno.2015.07.109 Open DOISearch in Google Scholar

34. Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2012; 125: 661–6. doi: 10.1016/j.ygyno.2012.02.037 GershensonDM SunCC IyerRB MalpicaAL KavanaghJJ BodurkaDC Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum Gynecol Oncol 2012 125 661 6 10.1016/j.ygyno.2012.02.037 Open DOISearch in Google Scholar

35. Power L, Lefas G, Lambert P, Kim D, Evaniuk D, Lotocki R, et al. Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival. Obstet Gynecol 2016; 126: 837–47. doi: 10.1097/AOG.0000000000001396 PowerL LefasG LambertP KimD EvaniukD LotockiR Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival Obstet Gynecol 2016 126 837 47 10.1097/AOG.0000000000001396 Open DOISearch in Google Scholar

36. Ploch, E. Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment. Gynecol Oncol 1987; 26: 169–77. doi: 10.1016/0090-8258(87)90270-8 PlochE Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment Gynecol Oncol 1987 26 169 77 10.1016/0090-8258(87)90270-8 Open DOISearch in Google Scholar

37. Rizzuto I, Oehler MK, Lalondrelle S. Sexual and psychosexual consequences of treatment for gynaecological cancers. Clin Oncol (R Coll Radiol) 2021; 33: 602–7. doi: 10.1016/j.clon.2021.07.003 RizzutoI OehlerMK LalondrelleS Sexual and psychosexual consequences of treatment for gynaecological cancers Clin Oncol (R Coll Radiol) 2021 33 602 7 10.1016/j.clon.2021.07.003 Open DOISearch in Google Scholar

38. Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med 2014; 11: 487–97. doi: 10.1111/jsm.12377 CuiY ZongH YanH LiN ZhangY The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis J Sex Med 2014 11 487 97 10.1111/jsm.12377 Open DOISearch in Google Scholar

39. Simon JA, Lin VH, Radovich C, Bachmann GA; Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013; 20: 418–27. doi: 10.1097/gme.0b013e31826d36ba SimonJA LinVH RadovichC BachmannGA Ospemifene Study Group One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus Menopause 2013 20 418 27 10.1097/gme.0b013e31826d36ba Open DOISearch in Google Scholar

40. Simon J, Portman D, Mabey RG; Ospemifene Study Group. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas 2014; 77: 274–81. doi: 10.1016/j.maturitas.2013.12.005 SimonJ PortmanD MabeyRG Ospemifene Study Group Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women Maturitas 2014 77 274 81 10.1016/j.maturitas.2013.12.005 Open DOISearch in Google Scholar

41. Barton DL, Shuster LT, Dockter T, Atherton PJ, Thielen J, Birrell SN, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer 2018; 26: 1335–43. doi: 10.1007/s00520-017-3960- BartonDL ShusterLT DockterT AthertonPJ ThielenJ BirrellSN Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance) Support Care Cancer 2018 26 1335 43 10.1007/s00520-017-3960- Open DOISearch in Google Scholar

42. Labrie F, Archer DF, Koltun W, Andrée Vachon, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016; 23: 243–56. doi: 10.1097/GME.0000000000000571 LabrieF ArcherDF KoltunW VachonAndrée YoungD FrenetteL Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause Menopause 2016 23 243 56 10.1097/GME.0000000000000571 Open DOISearch in Google Scholar

43. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2015; 33: 3394–400. doi: 10.1200/JCO.2014.60.7366 GoetschMF LimJY CaugheyAB A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial J Clin Oncol 2015 33 3394 400 10.1200/JCO.2014.60.7366 Open DOISearch in Google Scholar

44. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016; 19: 151–61. doi: 10.3109/13697137.2015.1124259 EdwardsD PanayN Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016 19 151 61 10.3109/13697137.2015.1124259 Open DOISearch in Google Scholar

45. Karamanidis D, Tamiolakis D, Koutsougeras G, Tripsanas CH, Retzos K, Karidis S, et al. Cigarette smoking and the degree of maturation of the vaginal squamous epithelium in postmenopausal women. Clin Exp Obstet Gynecol 2001; 28: 274–76. PMID: 11838758 KaramanidisD TamiolakisD KoutsougerasG TripsanasCH RetzosK KaridisS Cigarette smoking and the degree of maturation of the vaginal squamous epithelium in postmenopausal women Clin Exp Obstet Gynecol 2001 28 274 76 11838758 Search in Google Scholar

46. Daily JW, Ko BS, Ryuk J, Liu M, Zhang W, Park S. Equol decreases hot flashes in postmenopausal women: a systematic review and meta-analysis of randomized clinical trials. J Med Food 2019; 22: 127–39. doi: 10.1089/jmf.2018.4265 DailyJW KoBS RyukJ LiuM ZhangW ParkS Equol decreases hot flashes in postmenopausal women: a systematic review and meta-analysis of randomized clinical trials J Med Food 2019 22 127 39 10.1089/jmf.2018.4265 Open DOISearch in Google Scholar

47. Caruso S, Cianci S, Fava V, Rapisarda AMC, Cutello S, Cianci A. Vaginal health of postmenopausal women on nutraceutical containing equol. Menopause 2018; 25: 430–35. doi: 10.1097/GME.0000000000001061 CarusoS CianciS FavaV RapisardaAMC CutelloS CianciA Vaginal health of postmenopausal women on nutraceutical containing equol Menopause 2018 25 430 35 10.1097/GME.0000000000001061 Open DOISearch in Google Scholar

48. Mortensen OE, Christensen SE, Løkkegaard E. The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: a state-of-the-art review. Acta Obstet Gynecol Scand 2022; 101: 657–92. doi: 10.1111/aogs.14353 MortensenOE ChristensenSE LøkkegaardE The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: a state-of-the-art review Acta Obstet Gynecol Scand 2022 101 657 92 10.1111/aogs.14353 Open DOISearch in Google Scholar

49. Perrone AM, Tesei M, Ferioli M, De Terlizzi F, Gatta AND, Boussedra S, et al. Results of a phase I-II study on laser therapy for vaginal side effects after radiotherapy for cancer of uterine cervix or endometrium. Cancers 2020; 12: 1639. doi: 10.3390/cancers12061639 PerroneAM TeseiM FerioliM De TerlizziF GattaAND BoussedraS Results of a phase I-II study on laser therapy for vaginal side effects after radiotherapy for cancer of uterine cervix or endometrium Cancers 2020 12 1639 10.3390/cancers12061639 Open DOISearch in Google Scholar

50. Charatsi D, Vanakara P, Evaggelopoulou E, Simopoulou F, Korfias D, Daponte A, et al. Vaginal dilator use to promote sexual wellbeing after radiotherapy in gynecological cancer survivors. Medicine 2022; 101: e28705. doi: 10.1097/MD.0000000000028705 CharatsiD VanakaraP EvaggelopoulouE SimopoulouF KorfiasD DaponteA Vaginal dilator use to promote sexual wellbeing after radiotherapy in gynecological cancer survivors Medicine 2022 101 e28705 10.1097/MD.0000000000028705 Open DOISearch in Google Scholar

51. Martins J, Vaz AF, Grion RC, Costa-Paiva L, Baccaro LF. Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial. BMC Cancer. 2021; 21: 682. doi: 10.1186/s12885-021-08274-w MartinsJ VazAF GrionRC Costa-PaivaL BaccaroLF Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial BMC Cancer 2021 21 682 10.1186/s12885-021-08274-w Open DOISearch in Google Scholar